Humacyte, Inc. Debt Instrument, Unamortized Discount
Humacyte, Inc. (HUMA) had Debt Instrument, Unamortized Discount of $2.91 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscount · last filed 2026-08-12
- 2026-06-30: Debt Instrument, Unamortized Discount $2.91M.
- 2026-03-31: Debt Instrument, Unamortized Discount $3.13M.
- 2025-12-31: Debt Instrument, Unamortized Discount $3.34M.
| Period end | Debt Instrument, Unamortized Discount |
|---|---|
| 2026-06-30 | $2.91M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.13M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.34M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |